Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.42% | 38.17 | 0.9% | $1158.92m | |
| JNJ | Johnson & Johnson | -1.13% | 147.97 | 0.7% | $862.62m | |
| MRK | Merck & Co., Inc. | 1.09% | 83.58 | 0.7% | $652.14m | |
| BMY | Bristol-Myers Squibb Co. | -0.63% | 63.24 | 1.0% | $639.81m | |
| ABBV | AbbVie, Inc. | -0.83% | 94.72 | 1.9% | $619.79m | |
| AZN | AstraZeneca Plc | -0.85% | 55.81 | 1.2% | $561.08m | |
| LLY | Eli Lilly & Co. | -0.90% | 150.44 | 1.1% | $406.70m | |
| NVS | Novartis AG | 0.52% | 85.37 | 0.2% | $149.02m | |
| GSK | GlaxoSmithKline Plc | -1.15% | 41.19 | 0.2% | $136.11m | |
| MIST | Milestone Pharmaceuticals, Inc. | -0.68% | 8.74 | 0.0% | $120.06m | |
| OPK | OPKO Health, Inc. | 2.86% | 4.86 | 11.2% | $116.06m | |
| NVO | Novo Nordisk A/S | -0.31% | 66.88 | 0.1% | $71.85m | |
| RGEN | Repligen Corp. | 2.33% | 146.26 | 7.1% | $69.88m | |
| PRNB | Principia Biopharma, Inc. | 5.11% | 91.80 | 0.0% | $59.25m | |
| SNY | Sanofi | -0.81% | 51.37 | 0.2% | $57.17m |
Company Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.